Genitourinary Cancer
Feature
Cervical Cancer Screening: US Clinicians Unclear About Best Practices
ACS guidelines mark a notable departure from prevailing practice.
From the Journals
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
Researchers estimate more than 9,000 survivors’ adherence to weight, physical activity, fruit and vegetable consumption, and alcohol intake...
News from the FDA/CDC
FDA Approves New Bladder Cancer Drug
The FDA declined an initial approval for the combination in May 2023.
From the Journals
New Screening Protocol May Improve Prostate Cancer Detection
A new trial assesses a screening intervention that aims to reduce unnecessary diagnoses of prostate cancer but still catch relevant cancers and...
Conference Coverage
How Long Should Active Surveillance Last?
New data “suggest that meticulous follow-up is needed over a longer time” than previous studies have shown.
From the Journals
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...
Latest News
Meat Linked to Higher Erectile Dysfunction Risk
NYU urologist discusses impact of a plant-based diet on heart health, prostate cancer, and sexual health.
Conference Coverage
How New ICI Combos Change Bladder Cancer Management
Immune checkpoint inhibitor combinations have restructured treatment guidelines for metastatic urothelial carcinoma.
Conference Coverage
No Routine Cancer Screening Option? New MCED Tests May Help
CanScan, MERCURY, and OncoSeek can detect a range of cancers and recognize the tissue of origin with high accuracy.
From the Journals
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
Conference Coverage
Circulating Tumor DNA Predicts Early Treatment Response in Patients With HER2-Positive Cancers
New study results suggest ctDNA dynamics provide an early window into predicting response to targeted therapies in patients with HER2-altered...